Suppressive therapy for oropharyngeal candidiasis: 100 mg orally once a day or 3 times a week.Initial episodes of oropharyngeal candidiasis: 100 mg orally once a day for 7 to 14 days.US CDC, NIH, and IDSA Recommendations for HIV-infected Patients:
Moderate to severe oropharyngeal candidiasis: 100 to 200 mg IV or orally once a day for 7 to 14 days.Oropharyngeal candidiasis: 200 mg IV or orally on the first day followed by 100 mg IV or orally once a dayĭuration of therapy: At least 2 weeks, to reduce the risk of relapse Unless frequent or severe recurrences, suppressive therapy generally not recommended.Suppressive therapy for vulvovaginal candidiasis: 150 mg orally once a week.Severe or recurrent vulvovaginal candidiasis: 100 to 200 mg orally once a day for at least 7 days.US CDC, National Institutes of Health (NIH), and IDSA Recommendations for HIV-infected Patients: Severe vulvovaginal candidiasis: 150 mg orally every 72 hours for 2 doses.Maintenance therapy for recurrent vulvovaginal candidiasis: 100 to 200 mg orally once a week for 6 months.Initial therapy for recurrent vulvovaginal candidiasis: 100 to 200 mg orally every 72 hours for 3 doses.Uncomplicated vulvovaginal candidiasis: 150 mg orally as a single dose.Complicated vulvovaginal candidiasis: 150 mg orally every 72 hours for 3 doses.Management of recurrent vulvovaginal candidiasis (after 10 to 14 days induction therapy): 150 mg orally once a week for 6 months.Uncomplicated vaginitis: 150 mg orally as a single dose.Infectious Diseases Society of America (IDSA) Recommendations: Cryptococcal Meningitis - Immunosuppressed Host.Cryptococcal Meningitis - Immunocompetent Host.
0 kommentar(er)
